
Two of my favorite stocks remain Eli Lilly & Company (LLY) and Novo Nordisk A/S (NVO), thanks to their GLP-1 weight loss drugs. Today, I want to draw your attention in particular to Nordisk, which reported results on Jan. 31.
NVO shares have been hitting record highs, as the Danish pharma company’s blockbuster weight-loss drugs drove a massive surge in sales and profits last year. Novo Nordisk reported that sales climbed 36% to $33.7 billion in 2023, while profits rose to $12.14 billion, or $2.70 per share.